Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALT study of ranibizumab PRN versus aflibercept bimonthly in wet age-related macular degeneration
NL-OMON44213Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in exudative macular degeneration comparing Ranibizumab PRN with Aflibercept bimonthly (2 arms). Started Nov 2014; status: active, not recruiting.
02
Drugs
ranibizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON44213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44213.